Publicacións en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (17)

2024

  1. Novel biomarkers and psoriasis associated cardiovascular risk

    Archives of Dermatological Research, Vol. 316, Núm. 5

2023

  1. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II)

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 70, Núm. 7, pp. 409-421

  2. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II)

    Medicina Intensiva, Vol. 47, Núm. 8, pp. 454-467

2022

  1. Neutrophil-to-lymphocyte ratio as a cardiovascular risk biomarker in psoriasis: A comprehensive review

    JEADV Clinical Practice, Vol. 1, Núm. 4, pp. 397-406

2019

  1. High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients

    BMC neurology, Vol. 19, Núm. 1, pp. 167

  2. Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients

    Journal of Critical Care, Vol. 51, pp. 117-121

  3. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2016

  1. Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS)

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 63, Núm. 1, pp. e1-e22

2015

  1. Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS)

    Medicina Intensiva, Vol. 39, Núm. 8, pp. 483-504

  2. Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction

    BMC Neurology, Vol. 15, Núm. 1

2014

  1. Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury

    PLoS ONE, Vol. 9, Núm. 4

  2. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio

    PLoS ONE, Vol. 9, Núm. 4

  3. Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients

    Thrombosis Research, Vol. 134, Núm. 1, pp. 182-186

2013

  1. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis

    Critical Care, Vol. 17, Núm. 3

2011

  1. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis

    Critical Care, Vol. 15, Núm. 2

2010

  1. Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis

    Critical Care

2009

  1. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

    Critical Care, Vol. 13, Núm. 5